Related Experiment Video

Updated: Aug 15, 2026

Rat Model of Blood-brain Barrier Disruption to Allow Targeted Neurovascular Therapeutics
08:43

Rat Model of Blood-brain Barrier Disruption to Allow Targeted Neurovascular Therapeutics

Published on: November 30, 2012

[Mechanism of resistance to antitumor agents--its involvement in blood-brain barrier]

T Tsuruo1

  • 1Institute of Molecular and Cellular Biosciences, University of Tokyo, Japan.

Yakugaku Zasshi : Journal of the Pharmaceutical Society of Japan
|July 1, 1995
PubMed

Insights

Tumor resistance to chemotherapy is a major challenge. The mdr1 gene product, P-glycoprotein, acts as a pump for cytotoxic agents, impacting cancer treatment efficacy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Multidrug resistance (MDR) in tumors significantly compromises cancer chemotherapy effectiveness.
  • The mdr1 gene encodes P-glycoprotein, a transmembrane efflux pump responsible for transporting cytotoxic drugs out of cancer cells.
  • P-glycoprotein's role in drug resistance and its presence in the blood-brain barrier are critical considerations in treatment strategies.

Purpose of the Study:

  • To elucidate the mechanism of multidrug resistance mediated by P-glycoprotein.
  • To discuss the physiological function of P-glycoprotein in the context of cancer therapy.
  • To explore the potential of P-glycoprotein inhibitors in overcoming drug resistance.

Main Methods:

  • Analysis of the mdr1 gene product, P-glycoprotein.
  • Investigation of P-glycoprotein's interaction with anticancer drugs and resistance-reversing agents.
  • Assessment of P-glycoprotein's ATPase activity.
  • Evaluation of P-glycoprotein function in the blood-brain barrier.

Main Results:

  • P-glycoprotein functions as an ATP-dependent efflux pump for various chemotherapeutic agents.
  • P-glycoprotein exhibits binding affinity for anticancer drugs and modulators like calcium channel blockers.
  • P-glycoprotein plays a crucial role in the blood-brain barrier, limiting drug entry into the central nervous system.
  • Understanding P-glycoprotein's mechanism is key to addressing therapeutic resistance.

Conclusions:

  • P-glycoprotein is a central mediator of multidrug resistance in cancer.
  • Targeting P-glycoprotein offers a potential strategy to reverse chemotherapy resistance.
  • The role of P-glycoprotein in the blood-brain barrier necessitates specific approaches for central nervous system-targeted therapies.

More Related Videos

A Simple and Reproducible Method to Prepare Membrane Samples from Freshly Isolated Rat Brain Microvessels07:13

A Simple and Reproducible Method to Prepare Membrane Samples from Freshly Isolated Rat Brain Microvessels

Published on: May 7, 2018

Predicting In Vivo Payloads Delivery using a Blood-brain Tumor-barrier in a Dish13:34

Predicting In Vivo Payloads Delivery using a Blood-brain Tumor-barrier in a Dish

Published on: April 16, 2019

Related Concept Videos

The Blood-brain Barrier00:49

The Blood-brain Barrier

Overview
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Physiological Barriers01:25

Physiological Barriers

Physiological barriers are semi-permeable cellular structures restricting drug diffusion into intracellular compartments and tissues. There are six types of physiological barriers: blood endothelial, cell membrane, blood-brain, blood-cerebrospinal fluid (CSF), blood-placenta, and blood-testis barriers.
The blood endothelial barrier is the most porous of these. It allows all small ionized, un-ionized, and lipophilic molecules to pass through the endothelial lining into the interstitial space...
Carrier-Mediated Transport01:06

Carrier-Mediated Transport

Carrier-mediated transport is a pivotal process in drug absorption, particularly for lipid-insoluble drugs, and encompasses facilitated diffusion and active transport. Facilitated diffusion allows drugs to move along their concentration gradient without energy expenditure, while active transport utilizes ATP to drive drug movement against this gradient.
Active transport involves two types of membrane-spanning transporters: uptake and efflux. Uptake transporters are expressed in the small...
Factors Affecting Drug Distribution: Physiological Barriers01:23

Factors Affecting Drug Distribution: Physiological Barriers

Drug distribution in the body is intricately regulated by various physiological barriers that control the passage of substances. These include the capillary endothelial barrier, the blood-brain, blood-cerebrospinal fluid, blood-placental, and blood-testis barriers.
The capillary endothelial barrier allows only smaller molecules below 600 Da (Daltons) to pass through. It also restricts drugs like heparin that are bound to blood components, limiting their movement within the bloodstream.
The...